Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) declared that its Board of Directors has approved a stock buyback program on Monday, December 9th, RTT News reports. The company plans to repurchase ...
Azelaprag, the company’s main clinical candidate, is an oral apelin receptor agonist designed to amplify the weight loss ...
Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.
Technology companies continue to hold most of the top spots in the annual Management Top 250 ranking of America’s best-run ...
CBS News reports that workplace violence at Allina Health's Abbott Northwestern Hospital has led to more than $83,000 in fines over the past year. Other news from the health industry is on the demand ...
Check out which seven states are set to have the highest electricity bills in the next few months. For the latest news, ...
Stock futures edged lower Monday morning as investors eye this week’s key inflation report. The Consumer Price Index (CPI) ...